Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Liposomal Annamycin

Small molecule · Cytotoxic · developed by Moleculin Biotech

Phase 1/2 Most advanced trial (none active)

MBRX Developer

2 Registered trials

What is Liposomal Annamycin?

Liposomal annamycin is a cytotoxic small molecule delivered intravenously. It is being studied in soft tissue sarcoma with pulmonary metastasis and acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Mechanism: Cytotoxic
Therapy area: Oncology
Developer: Moleculin Biotech, Inc. (MBRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05319587	Phase 1/2	Leukemia, Myeloid, Acute	Completed	MBRX
NCT04887298	Phase 1/2	Sarcoma,Soft Tissue	Completed	MBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Leukemia, Myeloid, AcutePulmonary MetastasisSarcoma,Soft Tissue

More from Moleculin Biotech

MOL4239 Phase 2 WP1122 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the MBRX page.

Follow MBRX, the company behind Liposomal Annamycin

See MBRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MBRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z